Publications
-
Assessment of “No Value Care” among People with Employer-Sponsored Insurance and Traditional Medicare
Read more: Assessment of “No Value Care” among People with Employer-Sponsored Insurance and Traditional MedicarePolicymakers and clinician consortia have identified low value care, defined as health care services that provide negligible clinical benefit to the patient when provided, as one way to curb excessive and inefficient medical spending. A previous HCCI report found that 18% of people with employer-sponsored insurance in 2019 received at least one low-value service, which…
-
HCCImpact 2024
Read more: HCCImpact 2024High and rising health care costs affect individuals, families, and businesses across the country, and they have for decades. Cost forces difficult choices between health care and other needs. The Health Care Cost Institute’s mission of using data and analytics to improve the US health care system recognizes that people are at the heart of health…
-
Commercial inpatient hospital price growth driven by system affiliation and nonprofit-status hospitals
Tags: Health Affairs
Read more: Commercial inpatient hospital price growth driven by system affiliation and nonprofit-status hospitalsRecent data from the Health Care Cost Institute (HCCI) show that growth in hospitals’ commercial inpatient prices was higher in system-affiliated and non-profit hospitals from 2012-2021. Key Findings: In the backdrop of a wave of hospital mergers, system-affiliated non-profit hospitals account for more than half of short-term general acute care hospitals in the US (from…
-
Five years since US first biosimilar market entry, first signs of savings attributed to biosimilars in the employer-sponsored insurance population
Read more: Five years since US first biosimilar market entry, first signs of savings attributed to biosimilars in the employer-sponsored insurance populationBiologic drugs treat a range of diseases such as cancer, diabetes, retinal diseases, Crohn’s disease and many other conditions. Despite accounting for use by just 2% of Americans, spending on biologics is a major driver of drug spending in the United States. Biologics often come with a hefty price tag; for example, the most commonly…
-
Price Markups for Clinical Labs: Employer-based Insurance Pays Hospital Outpatient Departments 3x Than Physician Offices and Independent Labs for Identical Tests
Read more: Price Markups for Clinical Labs: Employer-based Insurance Pays Hospital Outpatient Departments 3x Than Physician Offices and Independent Labs for Identical TestsThe Health Care Cost Institute (HCCI) in collaboration with West Health conducted an analysis of the high prices that employer-based insurance pays hospital outpatient departments for clinical lab tests. We found that insurers are paying, on average, 3 times more for common lab tests such as blood and urine test when billed by hospital outpatient…
-
Obesity Treatments Vary Between ESI and Medicaid Populations
Read more: Obesity Treatments Vary Between ESI and Medicaid PopulationsAccording to the most recent year of data available, an estimated 42% of adults have obesity and almost 20% of children are diagnosed with obesity. It is well documented that obesity prevalence and associated health care costs continue to rise. The Kaiser Family Foundation has estimated the average annual health spending for people enrolled in commercial insurance…
-
Data Brief: Menopause Diagnosis Steadily Increased from 2018-2022
Read more: Data Brief: Menopause Diagnosis Steadily Increased from 2018-2022Menopause is clinically defined as the end of a female’s menstrual cycle, but for many, this stage of life is marked by uncertainty and confusion. It is a period where information is vague, experience is poorly understood, and it leaves many women feeling isolated as they navigate the complex changes of aging. Each year, nearly…
-
HCCI Research Finds The Lower Costs, More Transparency Act Targets Substantial Portion of Administered Drug Spending
Read more: HCCI Research Finds The Lower Costs, More Transparency Act Targets Substantial Portion of Administered Drug SpendingThe Lower Costs, More Transparency Act (H.R. 5378) currently before Congress aims to increase price transparency in health care and address the high cost of prescription drugs. One of the provisions of the bill would change the way Medicare pays for physician administered drugs. Currently, Medicare pays a higher price for drugs that are administered…
-
Severe Maternal Morbidity Increased by 25% from 2017-2021 among those with Employer Sponsored Insurance
Read more: Severe Maternal Morbidity Increased by 25% from 2017-2021 among those with Employer Sponsored InsuranceThe CDC defines Severe Maternal Morbidity (SMM) as ‘unexpected outcomes of labor and delivery that result in significant short- or long-term consequences to a woman’s health.’ These outcomes are largely preventable and are an important indicator of maternal health care quality. The CDC reports that SMM has steadily increased in recent years, and the consequences…
